Filtern
Volltext vorhanden
- ja (2)
Gehört zur Bibliographie
- ja (2)
Dokumenttyp
- Dissertation (2)
Schlagworte
- Ratte (2) (entfernen)
Institut
- Theodor-Boveri-Institut für Biowissenschaften (2) (entfernen)
Alzheimer’s disease (AD) is a progressive neurodegenerative disease of the brain. Today AD is the most common form of dementia in elderly people. It is clinically characterized by a progressive loss of memory and later on a decline in higher cognitive functions. The pathological hallmarks of AD, consistently demonstrated in brain tissue of patients, are extracellular amyloid-β (Aβ plaques, intracellular neurofibrillary tangles of tau protein and a profound loss of mainly cholinergic and glutamatergic synapses and ultimatively neurons. Estimates foresee that more than 80 million individuals will be affected by the disease by 2040 due to population aging worldwide underlining the high medical need for this disease. In order to find suitable drugs for the treatment of AD, experimental model systems are utilized to explore potential drug candidates. Such an experimental system is hippocampal long-term potentiation (LTP), which is widely accepted as an in vitro model of cellular processes fundamentally involved in memory formation. The present thesis focuses on the establishment and validation of LTP in rat hippocampal slices to characterize memory enhancing drugs as a potential treatment of AD. First, a multi-slice recording system was set up enabling stable measurements of LTP for up to seven hours from several slices simultaneously (chapter 2). Then, distinct protocols to induce early and late CA1 LTP, resembling short-term and long-term memory, were established. They were validated by addressing the hallmarks accepted for these forms of LTP: protein-synthesis independence and NMDA receptor dependence without contribution of L-VDCCs for early LTP, as opposed to protein-synthesis and NMDA / L-VDCCs dependence for late LTP (chapter 3). As in AD patients a loss of mainly cholinergic and glutamatergic synapses is obvious, these validated forms of LTP were used to study drugs potentially being able to enhance cholinergic and/or glutamatergic neuronal functions. The effects of two drugs exclusively interfering with cholinergic function on LTP were tested: the α4β2 nicotinic acetylcholinergic receptor agonist TC-1827 (chapter 4) and the acetylcholine esterase inhibitor donepezil (chapter 5). Both drugs were found to increase early LTP, but to not affect late LTP. Furthermore, two drugs exclusively interfering with glutamatergic function were analyzed: the metabotropic glutamate 5 receptor postive allosteric modulator ADX-47273 (chapter 3) and the phosphodiesterase (PDE) 9A inhibitor BAY 73-6691 (chapter 5). ADX-47273 increased late LTP, but had no effect on early LTP, whereas BAY 73-6691 showed enhancing effects on both early and late LTP and even transformed early into late LTP. The same effects like for the PDE9A inhibitor were observed for the α7 nicotinic acetylcholinergic receptor partial agonist SSR180711 (chapter 4), which interferes with both, cholinergic and glutamatergic function. Thus, drugs facilitating glutamatergic function or both glutamatergic and cholinergic function seem to be more efficacious in enhancing LTP than drugs facilitating solely cholinergic function. To evaluate whether this finding also proves true for experimental circumstances mimicking decreased cognitive function together with pathophysiology in AD patients, the ability of the drugs to ameliorate LTP impaired by soluble Aβ oligomer was analyzed (chapter 6). Soluble Aβ oligomers, also referred to as amyloid-β derived diffusible ligands (ADDLs), are thought to a putative cause of AD. Here, they were demonstrated to impair early and late LTP to different extents by exclusively targeting NMDA receptors and/or their signaling. These results further contribute to the hypothesis that soluble Aβ oligomers cause synaptic dysfunction which might lead to cognitive decline seen in AD patients. Regarding drug effects, donepezil and TC-1827 slightly restored ADDLs induced impairment of early LTP, but had no effect on late LTP impaired by ADDLs. In contrast, both, SSR180711 and BAY 73-6691 completely rescued early as well as late LTP impaired by ADDLs. ADX-47273 had no restoring effect on ADDLs induced early LTP impairment, but partially restored late LTP impaired by ADDLs. Thus, the earlier finding of the present thesis was confirmed: drugs facilitating glutamatergic function not only seem to be more efficacious in enhancing LTP than drugs facilitating solely cholinergic function, but are also superior in ameliorating soluble Aβ oligomer induced LTP deficits. Therefore, from a preclinical perspective and based on the results of the present thesis, drugs interfering with glutamatergic function seem to have a high therapeutic potential as alternative treatment concerning cognitive deficits. Probably, they represent more efficacious approaches for the symptomatic treatment of AD than current treatments solely facilitating cholinergic function.
Lamin C2
(2000)
In der Kernlamina von Spermatozyten von Nagetieren sind die Lamin A-Genprodukte, Lamin A und C, durch eine meiosespezifische Splicingvariante ersetzt. Dieses Lamin C2 unterscheidet sich auffallend von den somatischen Varianten in Struktur, Menge und Verhalten. Durch eine ektopische Expression von Lamin C2 als EGFP-Lamin C2-Fusionsprotein in einer somatischen Zellinie zeigte sich, daß eine neuartige Hexapeptidsequenz (GNAEGR) am N-terminalen Ende des Proteins anstelle der C-terminal gelegenen CaaX-Box somatischer Lamine für die Interaktion mit der Kernhülle verantwortlich ist. So ermöglicht eine posttranslationelle Myristylierung des ersten Glycins ein Membrantargeting, bei dem der hydrophobe Myristinsäurerest vergleichbar dem hydrophoben Farnesylrest am Cystein der Caax-Box mit den Fettsäureresten der Kernmembran interagiert. Die Deletion des Hexapeptids im Fusionsprotein EGFP-Lamin C2 und die seine N-terminale Insertion in das Fusionsprotein EGFP-Lamin C - es besitzt keine Caax-Box - bestätigt, daß allein das Hexapeptid das Membrantargeting steuert: Die Deletionsmutante EGFP-Lamin C2 bleibt diffus im Kern verteilt, während sich die Insertionsmutante EGFP-Lamin C im Bereich der Kernperipherie anreichert. Eine weitere Besonderheit stellt die Verteilung von Lamin C2 innerhalb der Kernhülle dar, denn es verteilt sich nicht gleichmäßig wie alle bisher bekannten Lamine, sondern bildet zahlreiche Aggregate. Nicht nur in der Kernhülle von Spermatozyten, sondern auch als Fusionsprotein in somatischen Zellen exprimiert, zeigt Lamin C2 diese Akkumulationen. Überraschenderweise treten die Synaptonemal-komplexenden nur im Bereich dieser Lamin C2-Aggregate mit der Kernhülle in Kontakt. Es wird daher postuliert, daß die Lamin C2-Aggregate der lokalen Verstärkung der Kernhülle dienen und wichtig für die auf die Prophase beschränkte Anheftung der SC an die Kernhülle sind. Da zudem in einer Kurzzeitkultur von Pachytänspermatozyten, in der die Prophase künstlich beschleunigt wird, gezeigt werden konnte, daß Lamin C2 mit Ende der Prophase I noch vor dem Auflösen der eigentlichen Kernhülle nicht mehr nachweisbar ist, scheint ein Zusammenhang zwischen Lamin C2 in der Kernhülle und der Umorganisation des genetischen Materials zu bestehen.